Against a background of the globally strengthening R&D focus on rare diseases, Japan is seeing unusually fierce competition in the relatively small indication of Stargardt disease, a rare ophthalmologic disorder where outstanding medical needs remain high, and helped by potential fast-track regulatory treatment.
With no approved therapeutics on the market anywhere worldwide, the most advanced candidate in the country is emixustat, an oral...